Aytu BioPharma Inc. (AYTU)
1.01
-0.01 (-0.98%)
At close: Apr 17, 2025, 3:37 PM
1.01
0.00%
After-hours: Apr 17, 2025, 04:00 PM EDT
-0.98% (1D)
| Bid | 1.01 |
| Market Cap | 6.23M |
| Revenue (ttm) | 68.76M |
| Net Income (ttm) | -5.25M |
| EPS (ttm) | -2.08 |
| PE Ratio (ttm) | -0.49 |
| Forward PE | 0.74 |
| Analyst | n/a |
| Ask | 1.1 |
| Volume | 10,191 |
| Avg. Volume (20D) | 34,577 |
| Open | 0.99 |
| Previous Close | 1.02 |
| Day's Range | 0.98 - 1.02 |
| 52-Week Range | 0.95 - 3.45 |
| Beta | 0.07 |
About AYTU
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the...
Sector Healthcare
IPO Date Sep 25, 2008
Employees 102
Stock Exchange NASDAQ
Ticker Symbol AYTU
Website https://aytubio.com
2 months ago
-0.72%
Aytu BioPharma shares are trading higher after the...
Unlock content with
Pro Subscription
5 months ago
-11.43%
Aytu BioPharma shares are trading lower. The company reported Q1 financial results.
2 months ago · accessnewswire.com
Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial ResultsNet income of $0.8 million Adjusted EBITDA1 of $1.3 million Pediatric Portfolio net revenue up 86% sequentially First quarterly sequential prescription increase for both ADHD and Pediatric portfolios ...
